Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 18.7% from a year ago

Total equity stood at $273.67M at the end of Q1 FY2026, down 18.7% from a year earlier and up 10.3% from the prior quarter. Over 3 fiscal years it compounded at -33.2% a year.

Context

  • Total equity amounted to 78.1% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -18.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$273.67M+10.3% QoQ
Last fiscal yearDec 2025
$248.2M-35.2% YoY
Year agoMar 2025
$336.52M-18.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.7%——
1 year-35.2%——
3-year CAGR-33.2%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
248.2M USD
Year-over-year change
-35.2%
4-year CAGR
-28.1%

Total Equity vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -18.7% is the 6th highest of 11, against a peer median of -19.1%.
  • Total equity amounts to 78.1% of total assets for LYEL, versus a peer median of 69.7%.
LYEL Competitors
Total Equity for LYEL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$449.41M USD-5.1%-8.3%69.6%
ALLOAllogene Therapeutics, Inc.Mar 2026$278.88M USD-27.6%-24.0%70.4%
LYELLyell Immunopharma, Inc.Mar 2026$273.67M USD-18.7%-33.2%78.1%
KYTXKyverna Therapeutics, Inc.Mar 2026$195.58M USD-12.7%+70.7%76.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$158.03M USD+9.5%-11.0%75.8%
CABACabaletta Bio, Inc.Mar 2026$103.31M USD-15.0%+2.3%69.7%
SLNSilence Therapeutics plcMar 2026$49.4M USD+143.8%+41.3%42.9%
ALDXAldeyra Therapeutics, Inc.Mar 2026$42.16M USD-33.7%-33.6%63.4%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
GNLXGenelux CorporationMar 2026$22.92M USD-23.2%—70.8%
EDITEditas Medicine, Inc.Mar 2026$4.41M USD-92.9%-57.7%3.0%
Peer median (excluding LYEL) —-19.1%-11.0%69.7%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents293.83M123.55M145.65M105.6M60.18M
Short-term Investments320.97M516.6M400.58M264.93M187.04M
Net Receivables00000
Inventory00000
Other Current Assets011.14M8.46M9.07M13.72M
Total Current Assets626.29M651.3M554.69M379.59M260.94M
Property, Plant & Equipment (Net)166.64M166.27M142.32M72.94M53.64M
Goodwill00000
Intangible Assets00000
Long-term Investments330.53M115.04M48.51M32.01M19M
Tax Assets00000
Other Non-current Assets3.95M4.96M4.52M6.31M6.47M
Total Non-current Assets501.12M286.27M195.34M111.27M79.11M
Total Assets1.13B937.56M750.03M490.86M340.05M
Account Payables3.21M3.92M4.82M5.37M2.89M
Short-term Debt00000
Tax Payables00000
Deferred Revenue4.99M0002.54M
Other Current Liabilities28.25M22.16M8.8M22.72M13.71M
Total Current Liabilities46.74M37.03M34.52M53.79M49.41M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)79.67M0000
Other Non-current Liabilities4.57M4.11M3.66M3.25M517K
Total Non-current Liabilities150.88M67.28M60.56M54.25M42.44M
Total Liabilities197.62M104.31M95.08M108.04M91.85M
Common Stock24K25K25K29K2K
Retained Earnings(584.36M)(767.48M)(1B)(1.35B)(1.62B)
Accumulated OCI(1.62M)(7.6M)(94K)291K242K
Other Stockholders Equity00000
Minority Interest00000
Total Equity929.79M833.25M654.95M382.82M248.2M
Total Debt67.82M67.7M63.17M58.97M50.99M
Net Debt(226.01M)(55.85M)(82.48M)(46.63M)(9.19M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.